PTJ
IOVA icon

Paul Tudor Jones’s Iovance Biotherapeutics IOVA Stock Holding History

Paul Tudor Jones’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
293,989
+77,985
+36% +$296K ﹤0.01% 2267
2026
Q1 		$758K Buy
216,004
+36,510
+20% +$117K ﹤0.01% 2558
2025
Q4 		$490K Buy
179,494
+57,750
+47% +$134K ﹤0.01% 2732
2025
Q3 		$264K Buy
+121,744
New +$287K ﹤0.01% 3056
2025
Q2 		– Sell
-122,930
Closed -$409K – 3488
2025
Q1 		$409K Buy
+122,930
New +$634K ﹤0.01% 2394
2024
Q4 		– Sell
-218,927
Closed -$2.06M – 3248
2024
Q3 		$2.06M Sell
218,927
-80,958
-27% -$767K 0.01% 1186
2024
Q2 		$2.41M Buy
299,885
+55,269
+23% +$592K 0.01% 973
2024
Q1 		$3.63M Buy
244,616
+211,468
+638% +$2.46M 0.02% 762
2023
Q4 		$269K Buy
+33,148
New +$173K ﹤0.01% 2072
2023
Q3 		– Sell
-115,277
Closed -$812K – 2559
2023
Q2 		$812K Buy
115,277
+57,750
+100% +$413K 0.01% 1427
2023
Q1 		$351K Sell
57,527
-37,102
-39% -$256K 0.01% 1824
2022
Q4 		$605K Buy
94,629
+15,849
+20% +$124K 0.01% 1455
2022
Q3 		$755K Sell
78,780
-11,714
-13% -$135K 0.02% 1119
2022
Q2 		$999K Buy
90,494
+60,124
+198% +$788K 0.03% 884
2022
Q1 		$506K Sell
30,370
-57,162
-65% -$884K 0.01% 1274
2021
Q4 		$1.67M Buy
87,532
+39,550
+82% +$871K 0.03% 730
2021
Q3 		$1.18M Buy
+47,982
New +$1.13M 0.02% 1041
2021
Q2 		– Sell
-150,091
Closed -$4.75M – 1744
2021
Q1 		$4.75M Buy
+150,091
New +$6.22M 0.1% 196
2020
Q3 		– Sell
-31,938
Closed -$877K – 1415
2020
Q2 		$877K Buy
+31,938
New +$1.05M 0.04% 517
2017
Q4 		– Sell
-19,000
Closed -$147K – 1163
2017
Q3 		$147K Buy
+19,000
New +$120K ﹤0.01% 990
2015
Q2 		– Sell
-18,225
Closed -$221K – 1577
2015
Q1 		$221K Buy
+18,225
New +$205K 0.01% 1241

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Paul Tudor Jones's IOVA Position: Q2 2026 in Review

Paul Tudor Jones increased its Iovance Biotherapeutics (IOVA) stake by 36% in Q2 2026, buying an estimated $296K and bringing the position to 293,989 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

Paul Tudor Jones first reported a position in IOVA in Q1 2015 and has held it in 21 quarters since. The position peaked at $4.75M in Q1 2021. 289 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Paul Tudor Jones held 293,989 shares of Iovance Biotherapeutics worth $1.22M as of Q2 2026.
  • Paul Tudor Jones bought 77,985 Iovance Biotherapeutics shares in Q2 2026, an estimated $296K.
  • Iovance Biotherapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2267 holding.
  • Paul Tudor Jones first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 21 quarters since.
  • Paul Tudor Jones's Iovance Biotherapeutics position peaked at $4.75M in Q1 2021.
  • 289 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.